Hey there, bargain hunter. Let’s get one thing out of the way first.

Nobody was expecting this.

UnitedHealth Group posted Q2 adjusted earnings of $6.38 per share this morning. The Street was modeling $4.90. That is not a small miss. That is a 30% beat on a company with a $400 billion-plus market cap, on a day when the Nasdaq is sliding and chip stocks are getting punished. UNH stock jumped roughly 6% to 7% in early trading. The rest of the managed care sector followed it higher.

Here is the part worth sitting with.

This was not luck. The medical care ratio came in at 86.7%, about 180 basis points below what analysts expected. Medicare cost trends ran below the company’s own initial estimate of around 10% for the full year. UnitedHealthcare margins expanded 220 basis points year over year. Optum margins were up 160 basis points. The company raised its full-year 2026 EPS guidance from $18.45 to $18.95 all the way to a range of $19.50 to $20.00. Full-year revenue guidance held at greater than $439 billion.

Slight tangent, but it matters: Optum, the health services and data arm, generated $65.7 billion in Q2 revenue alone and supported more than 120 million consumers in the quarter. That business does not get enough attention. While the insurance headlines dominate, Optum is quietly one of the most vertically integrated healthcare platforms on the planet. It is the real long-term engine here.

Now for the honest part of the story, because bargain hunters do not get to skip the fine print.

Membership is declining. UnitedHealthcare served 48.5 million people in Q2, down about 525,000 from the prior quarter. Management is still expecting Medicare Advantage membership to contract in 2026, and has previously outlined a contraction range of roughly 1.3 million to 1.4 million members for the full year. Higher premiums and benefit design changes are creating affordability pressure. Commercial medical costs are still running above prior expectations, and management described the commercial margin recovery as a multi-year journey extending beyond 2027.

So what do you actually have here?

A business that just showed it can manage Medicare cost trends better than the market assumed. A business that is cutting prior authorization volume by 30% by year-end, partly through AI investments. A business raising its buyback program to at least $5 billion for 2026. And a stock that spent most of 2025 and early 2026 being avoided by almost everyone, now proving that the worst of the cost cycle may be behind it.

The sector read-through is worth watching. Elevance, CVS Health, Centene, and Molina all moved higher on the UNH print today. When the largest managed care company in the country shows up with an 18-cent EPS beat at $4.90 expected and delivers $6.38, it resets how investors think about cost trajectory across the whole group.

The question now is not whether Q2 was good. It was. The question is whether the commercial cost drag drags longer than hoped, and whether the membership losses eventually start pressuring premium income. Those are real risks. Management said commercial margin recovery may not fully materialize until 2027 or later.

Still. The stock spent a long time looking like a broken story. This quarter says otherwise.

• Q2 adjusted EPS: $6.38 vs. $4.90 expected (31% beat)
• Q2 revenue: $112.0 billion vs. $110.85 billion expected
• Medical loss ratio: 86.7% (180 bps below consensus)
• Full-year 2026 EPS guidance raised to $19.50 to $20.00
• Optum Q2 revenue: $65.7 billion, 160 bps margin expansion
• Medicare cost trend now expected below 10% for 2026
• Membership serving 48.5 million, down roughly 525,000 from Q1
• Share buybacks: at least $5 billion authorized for 2026

The turnaround has numbers behind it now. Whether you trust it to hold through 2027 is the only real debate left.